The Emerging Role of IGF2BP2 in Cancer Therapy Resistance: From Molecular Mechanism to Future Potential

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 27

PMID 39596216

Authors

Die Li

Shiqi Hu

Jiarong Ye

Chaojie Zhai

Jipeng Liu

Zuao Wang

Xinchi Zhou

Leifeng Chen

Fan Zhou

Affiliations

Soon will be listed here.

Abstract

Tumor resistance is one of the primary reasons for cancer treatment failure, significantly limiting the options and efficacy of cancer therapies. Therefore, overcoming resistance has become a critical factor in improving cancer treatment outcomes. IGF2BP2, as a reader of m6A methylation, plays a pivotal role in the post-transcriptional regulation of RNA through the methylation of m6A sites. It not only contributes to cancer initiation and progression but also plays a key role in tumor drug resistance. This review provides a comprehensive summary of the mechanisms by which IGF2BP2 contributes to therapy resistance, with the aim of improving the efficacy of chemotherapy in cancer treatment. Advancing research in this area is crucial for developing more effective therapies that could significantly improve the quality of life for cancer patients.

References

Wang W, Ding Y, Zhao Y, Li X . m6A reader IGF2BP2 promotes lymphatic metastasis by stabilizing DPP4 in papillary thyroid carcinoma. Cancer Gene Ther. 2023; 31(2):285-299. DOI: 10.1038/s41417-023-00702-2. View

Andre F, Schartz N, Movassagh M, Flament C, Pautier P, Morice P . Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360(9329):295-305. DOI: 10.1016/S0140-6736(02)09552-1. View

Xie Z, Luo H, Wang T, Wang L, Zhang J, Dong W . METTL3 inhibits BMSC apoptosis and facilitates osteonecrosis repair via an m6A-IGF2BP2-dependent mechanism. Heliyon. 2024; 10(10):e30195. PMC: 11112270. DOI: 10.1016/j.heliyon.2024.e30195. View

Fang H, Sun Q, Zhou J, Zhang H, Song Q, Zhang H . mA methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma. Mol Cancer. 2023; 22(1):99. PMC: 10288689. DOI: 10.1186/s12943-023-01791-1. View

Wang G, Zhuang T, Zhen F, Zhang C, Wang Q, Miao X . IGF2BP2 inhibits invasion and migration of clear cell renal cell carcinoma via targeting Netrin-4 in an mA-dependent manner. Mol Carcinog. 2024; 63(8):1572-1587. DOI: 10.1002/mc.23746. View

Fu L, Zhang D, Yi N, Cao Y, Wei Y, Wang W . Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression. Hum Cell. 2022; 35(5):1560-1576. DOI: 10.1007/s13577-022-00748-8. View

Jiang X, Guo S, Wang S, Zhang Y, Chen H, Wang Y . EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling. Cancer Res. 2021; 82(5):831-845. DOI: 10.1158/0008-5472.CAN-21-2988. View

Mirzaei S, Gholami M, Hashemi F, Zabolian A, Farahani M, Hushmandi K . Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today. 2021; 27(2):436-455. DOI: 10.1016/j.drudis.2021.09.020. View

Schaeffer V, Hansen K, Morris D, LeBoeuf R, Abrass C . RNA-binding protein IGF2BP2/IMP2 is required for laminin-β2 mRNA translation and is modulated by glucose concentration. Am J Physiol Renal Physiol. 2012; 303(1):F75-82. PMC: 3431147. DOI: 10.1152/ajprenal.00185.2012. View

10.

Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B . High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006; 108(12):3898-905. DOI: 10.1182/blood-2006-04-014845. View

11.

Chen J, Wu X, Yin D, Jia X, Chen X, Gu Z . Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines. Pharmacol Ther. 2023; 249:108485. DOI: 10.1016/j.pharmthera.2023.108485. View

12.

Duan M, Liu H, Xu S, Yang Z, Zhang F, Wang G . IGF2BPs as novel mA readers: Diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment. Genes Dis. 2023; 11(2):890-920. PMC: 10491980. DOI: 10.1016/j.gendis.2023.06.017. View

13.

Lin Z, Huang Z, Qiu J, Shi Y, Zuo D, Qiu Z . mA-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma. J Exp Clin Cancer Res. 2024; 43(1):206. PMC: 11271202. DOI: 10.1186/s13046-024-03134-4. View

14.

Weng H, Huang F, Yu Z, Chen Z, Prince E, Kang Y . The mA reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022; 40(12):1566-1582.e10. PMC: 9772162. DOI: 10.1016/j.ccell.2022.10.004. View

15.

Peng F, Xu J, Cui B, Liang Q, Zeng S, He B . Oncogenic AURKA-enhanced N-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. Cell Res. 2020; 31(3):345-361. PMC: 8027457. DOI: 10.1038/s41422-020-00397-2. View

16.

Zhang C, Xu C, Gao X, Yao Q . Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022; 12(5):2115-2132. PMC: 8899578. DOI: 10.7150/thno.69424. View

17.

Yuan J, Li X, Wang F, Liu H, Guan W, Xu G . Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer. Exp Biol Med (Maywood). 2023; 248(23):2198-2209. PMC: 10903241. DOI: 10.1177/15353702231214268. View

18.

Dong H, Zeng L, Chen W, Zhang Q, Wang F, Wu Y . N6-methyladenine-mediated aberrant activation of the lncRNA SOX2OT-GLI1 loop promotes non-small-cell lung cancer stemness. Cell Death Discov. 2023; 9(1):149. PMC: 10164154. DOI: 10.1038/s41420-023-01442-w. View

19.

Lu S, Han L, Hu X, Sun T, Xu D, Li Y . N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer. J Hematol Oncol. 2021; 14(1):188. PMC: 8574039. DOI: 10.1186/s13045-021-01204-0. View

20.

Chen X, Wang J, Tahir M, Zhang F, Ran Y, Liu Z . Current insights into the implications of m6A RNA methylation and autophagy interaction in human diseases. Cell Biosci. 2021; 11(1):147. PMC: 8314498. DOI: 10.1186/s13578-021-00661-x. View